NextFin News - Swiss dental technology startup vVardis is moving forward with plans for an initial public offering in the United States, according to people familiar with the matter, marking a significant attempt by a European medtech firm to tap into the deep liquidity of American capital markets. The Zurich-based company, founded by sisters Haley and Goly Abivardi, has reportedly engaged JPMorgan Chase & Co. and Goldman Sachs Group Inc. to lead the potential listing, which could value the firm at over $1 billion.
The timing of the move coincides with a broader resurgence in the IPO market under U.S. President Trump’s administration, which has signaled a preference for deregulation and corporate growth. vVardis has gained international attention for its proprietary "Curolox" technology, a biomimetic process that allows for the non-invasive treatment of early-stage cavities by regenerating tooth enamel. This "drill-free" approach has been positioned as a disruptive force in a dental industry that has historically relied on mechanical intervention and synthetic fillings.
The Abivardi sisters are no strangers to the intersection of dentistry and high finance. Before founding vVardis, they built Swiss Smile, one of the largest networks of private dental clinics in Europe, which they eventually sold to the EQT-backed Colosseum Dental Group. Their latest venture has already secured high-profile endorsements; notably, JPMorgan CEO Jamie Dimon publicly praised the company’s innovation during the bank’s healthcare conference in San Francisco earlier this year. Such backing from the upper echelons of Wall Street suggests a strong institutional appetite for the company’s growth story.
However, the path to a successful IPO is not without hurdles. While the U.S. market offers higher valuations for growth-stage healthcare companies compared to European exchanges, vVardis faces the challenge of scaling its commercial operations in a highly fragmented American dental market. The company’s products, including the Curadont Repair treatment, require adoption by individual practitioners who may be slow to pivot from traditional billing models centered on fillings and crowns. Furthermore, the medtech sector remains sensitive to interest rate fluctuations, which can impact the discounted cash flow models used to justify billion-dollar valuations for pre-profit or early-profit entities.
Market analysts remain divided on whether the current "dealmaking renaissance" predicted by Goldman Sachs CEO David Solomon will provide a stable floor for specialized medtech listings. While Solomon has forecasted that 2026 will feature "unprecedented" IPO activity fueled by private equity exits and stabilizing rates, some institutional investors caution that the "Trump trade" volatility could lead to sudden shifts in risk appetite. For vVardis, the decision to list in New York rather than Zurich or London reflects a calculated bet that American investors will better appreciate the long-term value of preventative dental technology over immediate dividend yields.
Explore more exclusive insights at nextfin.ai.
